Leerink Partnrs Comments on Pyxis Oncology FY2029 Earnings

Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Research analysts at Leerink Partnrs issued their FY2029 earnings per share estimates for shares of Pyxis Oncology in a research note issued on Friday, May 16th. Leerink Partnrs analyst J. La. Rosa expects that the company will post earnings per share of ($0.29) for the year. The consensus estimate for Pyxis Oncology's current full-year earnings is ($1.04) per share.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.06).

Other equities research analysts have also recently issued reports about the stock. HC Wainwright restated a "buy" rating and set a $5.00 price target on shares of Pyxis Oncology in a report on Monday. Royal Bank of Canada reissued an "outperform" rating and set a $8.00 price objective on shares of Pyxis Oncology in a research report on Wednesday, March 19th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Pyxis Oncology presently has an average rating of "Moderate Buy" and an average target price of $9.00.

Pyxis Oncology Price Performance

NASDAQ:PYXS traded up $0.05 during midday trading on Monday, reaching $1.20. The stock had a trading volume of 281,700 shares, compared to its average volume of 737,587. The stock has a market capitalization of $74.34 million, a P/E ratio of -1.17 and a beta of 1.15. Pyxis Oncology has a 1-year low of $0.83 and a 1-year high of $5.39. The firm's fifty day simple moving average is $1.06 and its 200-day simple moving average is $1.59.

Institutional Trading of Pyxis Oncology

Hedge funds and other institutional investors have recently bought and sold shares of the stock. ProShare Advisors LLC acquired a new position in shares of Pyxis Oncology during the fourth quarter valued at about $26,000. Ameriprise Financial Inc. acquired a new stake in Pyxis Oncology during the fourth quarter worth about $35,000. Caption Management LLC bought a new position in Pyxis Oncology during the fourth quarter valued at about $35,000. Commonwealth Equity Services LLC raised its holdings in Pyxis Oncology by 61.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company's stock valued at $41,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Graham Capital Management L.P. acquired a new position in Pyxis Oncology in the 4th quarter valued at approximately $47,000. 39.09% of the stock is currently owned by institutional investors and hedge funds.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.